PATENT CLAIM ANALYSIS

Application Number: 15965246
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-04
Patent Classification: ["424", "186100"]

Abstract:
The present disclosure relates to recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.

Claim (Index 23):
The recombinant viral vector of  claim 22 , wherein the non-essential HCMV or RhCMV gene region is selected from the group consisting of: the RL11 family, the pp65 family, the US12 family, and the US28 family.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 91.0
- Lexical Diversity: 1.45
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14872756', '13694280', '15374938', '14179152', '14086602']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8282533605889247
- 35 USC 102 Novelty (BERT): 0.7055937492129951
- Combined Prediction Score: 0.8159873994513318
- Mean Citation Score: 626.7934600000002
- Max Citation Score: 779.808
- Similarity Product: 723.8420533103942

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test